These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10858672)

  • 1. The natural history of breast cancer--can anything be done about it?
    Sacks NP
    Med Leg J; 2000; 68 ( Pt 1)():16-29. PubMed ID: 10858672
    [No Abstract]   [Full Text] [Related]  

  • 2. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
    Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
    Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR imaging in screening women at increased risk for breast cancer.
    Boetes C; Stoutjesdijk M
    Magn Reson Imaging Clin N Am; 2001 May; 9(2):357-72, vii. PubMed ID: 11493425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The case for individualized screening recommendations for breast cancer.
    Bradbury A; Olopade OI
    J Clin Oncol; 2006 Jul; 24(21):3328-30. PubMed ID: 16801629
    [No Abstract]   [Full Text] [Related]  

  • 5. Survival from breast cancer in England and Wales up to 2001.
    Leary A; Smith IE
    Br J Cancer; 2008 Sep; 99 Suppl 1(Suppl 1):S56-8. PubMed ID: 18813261
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
    Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
    JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in the incidence and mortality of breast cancer in England and Wales since the introduction of screening].
    Estéve J
    Rev Epidemiol Sante Publique; 1996 Apr; 44(2):189-91. PubMed ID: 8693178
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Not Available].
    Seifert H; Siebenhüner A
    Praxis (Bern 1994); 2017 Jul; 106(14):745-752. PubMed ID: 28677487
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales.
    Waller M; Moss S; Watson J; Møller H
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2257-61. PubMed ID: 18006913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer screening with MRI--what are the data for patients at high risk?
    Liberman L
    N Engl J Med; 2004 Jul; 351(5):497-500. PubMed ID: 15282358
    [No Abstract]   [Full Text] [Related]  

  • 12. JAMA patient page. BRCA genes and breast cancer.
    Pluta RM; Golub RM
    JAMA; 2011 Jun; 305(21):2244. PubMed ID: 21632489
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent developments in the ability to predict and modify breast cancer risk.
    Prado A; Andrades P; Parada F
    J Plast Reconstr Aesthet Surg; 2010 Oct; 63(10):1581-7. PubMed ID: 19666246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the Cost-Effectiveness of Alternative Upper Age Limits for Breast Cancer Screening in England and Wales.
    Rafia R; Brennan A; Madan J; Collins K; Reed MW; Lawrence G; Robinson T; Greenberg D; Wyld L
    Value Health; 2016 Jun; 19(4):404-12. PubMed ID: 27325332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and follow-up of the patient at high risk for breast cancer.
    Willey SC; Cocilovo C
    Obstet Gynecol; 2007 Dec; 110(6):1404-16. PubMed ID: 18055740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit.
    Maurice A; Evans DG; Affen J; Greenhalgh R; Duffy SW; Howell A
    Int J Cancer; 2012 Jul; 131(2):417-25. PubMed ID: 21898384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annual or biennial mammography screening for women at a higher risk with a family history of breast cancer: prognostic indicators of screen-detected cancers in New South Wales, Australia.
    Randall D; Morrell S; Taylor R; Hung WT
    Cancer Causes Control; 2009 Jul; 20(5):559-66. PubMed ID: 19015941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer population screening by single view mammography with selective clinical examination--a pilot study.
    Thomas BA; Price JL; Boulter PS
    Clin Oncol; 1981 Sep; 7(3):201-4. PubMed ID: 7343165
    [No Abstract]   [Full Text] [Related]  

  • 20. The value of risk factors in screening for breast cancer.
    Stark AM
    Eur J Surg Oncol; 1985 Jun; 11(2):147-50. PubMed ID: 4007172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.